Section Arrow
ACRS.NASDAQ
- Aclaris Therapeutics
Quotes are at least 15-min delayed:2024/04/28 05:54 EDT
Last
 1.2
+0.01 (+0.84%)
Day High 
1.2 
Prev. Close
1.19 
1-M High
1.32 
Volume 
445.22K 
Bid
1.19
Ask
1.2
Day Low
1.16 
Open
1.2 
1-M Low
1.14 
Market Cap 
84.40M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.21 
20-SMA 1.21 
50-SMA 1.22 
52-W High 11.12 
52-W Low 0.5902 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.27/-0.62
Enterprise Value
95.05M
Balance Sheet
Book Value Per Share
2.22
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
31.25M
Operating Revenue Per Share
0.30
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LABStandard BioTools2.44+0.08+3.39%-- 
DHRDanaher Corp246.58+0.78+0.32%45.1PE
ME23andMe Holding Co0.4641+0.0051+1.11%-- 
NEOGNeogen Corp12.14+0.18+1.51%598PE
EXASExact Sciences Corp58.85+0.06+0.10%-- 
Quotes are at least 15-min delayed:2024/04/28 05:54 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; andATI-1777.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.